Rosenberg Matthew Hamilton Has $79,000 Stock Holdings in McKesson Co. (NYSE:MCK)

Rosenberg Matthew Hamilton grew its stake in shares of McKesson Co. (NYSE:MCK) by 1,163.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 139 shares of the company’s stock after buying an additional 128 shares during the quarter. Rosenberg Matthew Hamilton’s holdings in McKesson were worth $79,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Traveka Wealth LLC acquired a new stake in McKesson in the 4th quarter valued at $237,000. Unique Wealth LLC boosted its stake in McKesson by 10.0% during the 4th quarter. Unique Wealth LLC now owns 1,672 shares of the company’s stock valued at $953,000 after purchasing an additional 152 shares during the last quarter. CHB Investment Group LLC increased its holdings in McKesson by 0.6% during the 4th quarter. CHB Investment Group LLC now owns 4,607 shares of the company’s stock worth $2,626,000 after purchasing an additional 26 shares in the last quarter. Signet Financial Management LLC raised its stake in shares of McKesson by 1.3% in the fourth quarter. Signet Financial Management LLC now owns 4,065 shares of the company’s stock worth $2,317,000 after purchasing an additional 51 shares during the last quarter. Finally, Peddock Capital Advisors LLC lifted its holdings in shares of McKesson by 0.5% in the fourth quarter. Peddock Capital Advisors LLC now owns 8,031 shares of the company’s stock valued at $4,577,000 after purchasing an additional 43 shares in the last quarter. Institutional investors own 85.07% of the company’s stock.

Insider Transactions at McKesson

In related news, EVP Leann B. Smith sold 579 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total transaction of $331,645.41. Following the sale, the executive vice president now owns 864 shares of the company’s stock, valued at approximately $494,890.56. This represents a 40.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.11% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Bank of America decreased their price target on McKesson from $680.00 to $650.00 and set a “buy” rating for the company in a report on Monday, January 6th. Leerink Partners lowered their target price on shares of McKesson from $665.00 to $630.00 and set an “outperform” rating for the company in a report on Monday, October 7th. Baird R W raised shares of McKesson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 7th. Mizuho assumed coverage on shares of McKesson in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $630.00 price objective for the company. Finally, StockNews.com raised shares of McKesson from a “hold” rating to a “buy” rating in a research report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $646.14.

McKesson Stock Performance

Shares of McKesson stock opened at $594.11 on Wednesday. The stock has a market capitalization of $75.42 billion, a P/E ratio of 30.77, a P/E/G ratio of 1.25 and a beta of 0.52. McKesson Co. has a 52-week low of $464.42 and a 52-week high of $637.51. The stock’s 50-day simple moving average is $595.09 and its 200 day simple moving average is $560.90.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $7.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.88 by $0.19. The company had revenue of $93.65 billion for the quarter, compared to analyst estimates of $89.33 billion. McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. The company’s quarterly revenue was up 21.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.23 earnings per share. Equities research analysts forecast that McKesson Co. will post 32.73 EPS for the current fiscal year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, January 2nd. Shareholders of record on Monday, December 2nd were given a dividend of $0.71 per share. The ex-dividend date was Monday, December 2nd. This represents a $2.84 annualized dividend and a dividend yield of 0.48%. McKesson’s dividend payout ratio is currently 14.71%.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.